154 related articles for article (PubMed ID: 38515208)
41. Is Ki-67 expression prognostic for local relapse in early-stage breast cancer patients treated with breast conservation therapy (BCT)?
Hafeez F; Neboori HJ; Harigopal M; Wu H; Haffty BG; Yang Q; Schiff D; Moran MS
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):344-8. PubMed ID: 23910708
[TBL] [Abstract][Full Text] [Related]
42. Clinical, Epidemiologic, and Pathologic Significance of ERBB2-Low Expression in Breast Cancer.
Khoury T; Mendicino L; Payne Ondracek R; Yao S; Davis W; Omilian AR; Kwan ML; Roh JM; D'Addario L; Valice E; Fernandez D; Ergas IJ; Chua AV; Ambrosone CB; Kushi LH
JAMA Netw Open; 2024 Mar; 7(3):e243345. PubMed ID: 38517439
[TBL] [Abstract][Full Text] [Related]
43. BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.
Hamy AS; Bieche I; Lehmann-Che J; Scott V; Bertheau P; Guinebretière JM; Matthieu MC; Sigal-Zafrani B; Tembo O; Marty M; Asselain B; Spyratos F; de Cremoux P
Breast Cancer Res Treat; 2016 Oct; 159(3):499-511. PubMed ID: 27592112
[TBL] [Abstract][Full Text] [Related]
44. Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.
Kong X; Liu Z; Cheng R; Sun L; Huang S; Fang Y; Wang J
JAMA Netw Open; 2020 Oct; 3(10):e2020303. PubMed ID: 33074325
[TBL] [Abstract][Full Text] [Related]
45. Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors.
Warner ET; Tamimi RM; Hughes ME; Ottesen RA; Wong YN; Edge SB; Theriault RL; Blayney DW; Niland JC; Winer EP; Weeks JC; Partridge AH
J Clin Oncol; 2015 Jul; 33(20):2254-61. PubMed ID: 25964252
[TBL] [Abstract][Full Text] [Related]
46. HER2 status and disparities in luminal breast cancers.
Holowatyj AN; Ruterbusch JJ; Ratnam M; Gorski DH; Cote ML
Cancer Med; 2016 Aug; 5(8):2109-16. PubMed ID: 27250116
[TBL] [Abstract][Full Text] [Related]
47. Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts.
Oparina N; Erlandsson MC; Fäldt Beding A; Parris T; Helou K; Karlsson P; Einbeigi Z; Bokarewa MI
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34064473
[TBL] [Abstract][Full Text] [Related]
48. Age, Body Mass Index, Tumor Subtype, and Racial and Ethnic Disparities in Breast Cancer Survival.
Lipsyc-Sharf M; Ballman KV; Campbell JD; Muss HB; Perez EA; Shulman LN; Carey LA; Partridge AH; Warner ET
JAMA Netw Open; 2023 Oct; 6(10):e2339584. PubMed ID: 37878313
[TBL] [Abstract][Full Text] [Related]
49. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.
Ihemelandu CU; Leffall LD; Dewitty RL; Naab TJ; Mezghebe HM; Makambi KH; Adams-Campbell L; Frederick WA
J Surg Res; 2007 Nov; 143(1):109-18. PubMed ID: 17950079
[TBL] [Abstract][Full Text] [Related]
50. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
Bauer KR; Brown M; Cress RD; Parise CA; Caggiano V
Cancer; 2007 May; 109(9):1721-8. PubMed ID: 17387718
[TBL] [Abstract][Full Text] [Related]
51. Abstract PS6-55: The prognostic utility of AR/ER ratio in young women with breast cancer.
Prabhu JS; Korlimarla A; Rajarajan S; Alexander A; Anupama C; Ramesh R; Srinath B; Sridhar TS
Cancer Res; 2021 Feb; 81(4 Suppl):. PubMed ID: 34421401
[TBL] [Abstract][Full Text] [Related]
52. Racial disparity in distant recurrence-free survival in patients with localized breast cancer: A pooled analysis of National Surgical Adjuvant Breast and Bowel Project trials.
Kim G; Pastoriza JM; Qin J; Lin J; Karagiannis GS; Condeelis JS; Yothers G; Anderson S; Julian T; Entenberg D; Rohan TE; Xue X; Sparano JA; Oktay MH
Cancer; 2022 Jul; 128(14):2728-2735. PubMed ID: 35578919
[TBL] [Abstract][Full Text] [Related]
53. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
54. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
[TBL] [Abstract][Full Text] [Related]
55. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
Chen L; Cook LS; Tang MT; Porter PL; Hill DA; Wiggins CL; Li CI
Breast Cancer Res Treat; 2016 Jun; 157(3):545-54. PubMed ID: 27220749
[TBL] [Abstract][Full Text] [Related]
56. Expression of survivin does not appear to influence breast cancer recurrence risk.
Collin LJ; Cronin-Fenton DP; Ahern TP; Christensen KB; Damkier P; Hamilton-Dutoit S; Kjaersgaard A; Lauridsen KL; Yacoub R; Christiansen P; Sørensen HT; Lash TL
Acta Oncol; 2019 Feb; 58(2):154-161. PubMed ID: 30351173
[TBL] [Abstract][Full Text] [Related]
57. Epigenetic Profiles of Triple-Negative Breast Cancers of African American and White Females.
Ensenyat-Mendez M; Solivellas-Pieras M; Llinàs-Arias P; Íñiguez-Muñoz S; Baker JL; Marzese DM; DiNome ML
JAMA Netw Open; 2023 Oct; 6(10):e2335821. PubMed ID: 37796506
[TBL] [Abstract][Full Text] [Related]
58. Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis.
Ma H; Ursin G; Xu X; Lee E; Togawa K; Malone KE; Marchbanks PA; McDonald JA; Simon MS; Folger SG; Lu Y; Sullivan-Halley J; Deapen DM; Press MF; Bernstein L
Breast Cancer Res; 2018 Jan; 20(1):5. PubMed ID: 29357906
[TBL] [Abstract][Full Text] [Related]
59. Associations of hormone-related factors with breast cancer risk according to hormone receptor status among white and African American women.
Cui Y; Deming-Halverson SL; Shrubsole MJ; Beeghly-Fadiel A; Fair AM; Sanderson M; Shu XO; Kelley MC; Zheng W
Clin Breast Cancer; 2014 Dec; 14(6):417-25. PubMed ID: 24970715
[TBL] [Abstract][Full Text] [Related]
60. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
